Blog

Quick Hit – MIBG:Indications, Side Effects, Monitoring and Follow-Up

Presentation Description: Neuroblastoma is the most common extracranial malignant tumour of childhood and accounts for 15% of all pediatric cancer deaths. On diagnosis, 50% of the children present with metastatic disease. Despite the intensive multimodality therapy, patients with high-risk neuroblastoma have a less than 40% survival rate. It is known that refractory or relapsed neuroblastoma is extremely difficult to treat. Treatment with Iodine-131 – labeled meta-iodobenzylguanidine (131 I-MIBG) has shown to be safe and efficacious in patients with progressive, refractory or relapsed high-risk neuroblastoma. This quick- hit presentation briefly described Indications of 131I-MIGB therapy, side effects, monitoring and supportive care of the patient and family.

Speaker:
Denise Mills, MN, RN(EC)
Nurse Practitioner
The Hospital for Sick Children, Toronto, ON

Comments are closed.